Management of hypertension in diabetes

Diabetes Spectrum

Volumn 19, Issue 1, 2006, Pages 25-31

  Stults, Barry ^a   Jones, Robert E ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; EPLERENONE; FELODIPINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOOP DIURETIC AGENT; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; VALSARTAN; VERAPAMIL;

ALCOHOL CONSUMPTION; ALGORITHM; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIABETIC ANGIOPATHY; DIABETIC HYPERTENSION; DIET THERAPY; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; EXERCISE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; META ANALYSIS; MICROALBUMINURIA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SODIUM RESTRICTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 33344455652     PISSN: 10409165     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaspect.19.1.25     Document Type: Review

References (61)

1. Beckman JA, Crenger MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570-2581, 2002
2. Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, Hsueh W, Rewers M, Roberts BT, Savage PJ, Skarlatos S, Wassef M, Rabadan-Diehl C: Report of the National Heart, Lung, and Blood Institute: National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 111:3489-3493, 2005
3. National Kidney Foundation: Guideline 8: pharmacological therapy: diabetic kidney disease. Am J Kidney Dis 43 (Suppl. 1):S142-S159, 2004
4. Fong DS, Aiello LP, Ferris FL 3rd, Klein R: Diabetic retinopathy. Diabetes Care 27:2540-2553, 2004
5. Tesfaye S, Chat́urvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH: Vascular risk factors and diabetic neuropathy. N Engl J Med 352:341-350, 2005
6. Sowers JR, Epstein M, Frolich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37:1053-1059, 2001
7. Centers for Disease Control: National Diabetes Fact Sheet 1/31/05 [article online]. Available from www.cdc.gov/diabetes/pubs/estimates.htm. Accessed 24 July 2005
8. American Diabetes Association: Standards of medical care in diabetes (Position Statement), Diabetes Care 28 (Suppl. 1):S4-S36, 2005
9. Hemmelgarn BR, McAlister FA, Myers MG, McKay DW, Bolli P, Abbott C, Schiffrin EL, Grover S, Honos G, Lebel M, Mann K, Wilson T, Penner B, Tremblay G, Tobe SW, Feldman RD: The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension. Can J Cardiol 21:645-656, 2005
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42:1206-1252, 2003
11. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S: Guidelines for the management of hypertension: report of the Fourth Working Party of the British Hypertension Society, 2004. J Human Hypertens 18:139-185, 2004
12. European Societies of Hypertension and Cardiology: Guidelines for the management of arterial hypertension, 2003. J Hypertens 21:1011-1052, 2003
13. Maahs DM, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson J, Ehrlich J, Garg S, Eckel RH, Rewers MJ: Hypertension prevalence, awareness, treatment, and control in an adult type 1 diabetes population and a comparable general population. Diabetes Care 28:301-306, 2005
14. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 276:1886-1892, 1996
15. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340:677-684, 1999
16. UKPDS Group: UK Prospective Diabetes Study 38: tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 317:703-713, 1998
17. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomized trial. Lancet 351:1755-1762, 1998
18. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetics on albuminuria, retinopathy, and strokes. Kidney Int 61:1086-1097, 2002
19. Adler AI, Stratton IM, Neil HA, Judkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412-419, 2000
20. Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R, Pepine CJ: Clinical outcomes in the diabetic cohort of the International Verapamil SR-Trandolapril Study. Hypertension 44:643-648, 2004
21. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ: Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 16:2170-2179, 2005
22. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
23. CDC Diabetes Cost-effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542-2551, 2002
24. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291:335-342, 2004
25. McFarlane SI, Castro J, Kaur J, Shin JJ, Kelling D Jr, Farag A, Simon N, El-Atat F, Sacerdote A, Basta E, Flack J, Bakris G, Sowers JR: Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens 7:73-80, 2005
26. Grant RW, Buse JB, Meigs JB: Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care 28:337-342, 2005
27. Zgibor JC, Wilson RR, Orchard TJ: Has control of hypercholesterolemia and hypertension in type 1 diabetes improved over time? Diabetes Care 28:521-526, 2005
28. Majernick TG, Zacker C, Madden NA, Belletti DA, Arcona S: Correlates of hypertension control in a primary care setting. Am J Hypertens 17:915-920, 2004
29. Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Palmer CR, Rosenthal T, Ruilope LM: Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 35:1038-1042, 2000
30. Bakris G, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS: Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized clinical trial. JAMA 292:2227-2236, 2004
31. Merz CN, Buse JB, Tuncer D, Twillman BG: Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol 40:1877-1881, 2002
32. Grant RW, Cagliero E, Dubey AK, Gildesgame C, Chueh HC, Barry MJ, Singer DE, Nathan DM, Meigs JB: Clinical inertia in the management of type 2 diabetes metabolic risk factors, Diabet Med 21:150-155, 2004
33. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 363:2049-2051, 2004
34. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Rocella EJ: Recommendations for blood pressure measurement in humans and experimental animals. Part 1. Blood pressure measurement in humans. Hypertension 45:142-161, 2005
35. Grewal J, Lonn E: Surrogates of surrogates: the story of hypertension and 24-hour blood pressure monitoring. Can J Cardiol 21:639-642, 2005
36. American Diabetes Association: Physical activity/exercise and diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S58-S62, 2004
37. Rahman M, Pressel S, Davis BR, Nwachuku, C, Wright JT Jr, Whelton PK, Barzilay J, Bataman V, Eckfeldt JH, Farber M, Henriquez M, Kopy TN, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Weimann T, for the ALLHAT Collaborative Research Group: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the ALLHAT Trial. Arch Intern Med 165:936-946, 2005
38. Blood Pressure Lowering Treatment Trialists' Collaboration: Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165:1410-1419, 2005
39. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iliamathi E, Dostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Parebianco D, Parish DC, Pressel S, Simmons DL, Thadani U, ALLHAT Collaborative Research Group: Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165:1401-1409, 2005
40. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Neiminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in Hypertension study (LIFE): a randomized trial against atenolol. Lancet 359:1004-1010, 2002
41. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
42. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML, on behalf of the EUROPA Investigators: The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 26:1369-1378, 2005
43. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J: Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 38:E28-E32, 2001.
44. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ehe-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G, Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941-1951, 2004
45. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952-1961, 2004
46. Andersen NH, Poulsen PL, Knudsen ST, Poulsen SH, Eiskjaer H, Hansen KW, Helleberg K, Mogensen CE: Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes. Diabetes Care 28:273-277, 2005
47. Doulton TWR, He FJ, MacGregor GA: Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45:880-886, 2005
48. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH: Aldosterone escape during angiotensin II receptor blockade in diabetic nephropathy is associated with enhanced decline in GFR. Diabetologia 47:1936-1939, 2004
49. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving H-H: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28:2106-2112, 2005
50. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, Ravid M: The effect of spironolactone, cilazapril, and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled trial. Diabet Med 21:471-475, 2004
51. Black HR: Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data. Am Heart J 147:564-572, 2004
52. PROGRESS Collaborative Group: Randomized trial of perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet 358:1033-1041, 2002
53. Franse LV, Pahor M, DiBari M, Somes GW, Cushman WC, Applegate WB: Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 35:1025-1030, 2000
54. Nathan S, Pepine CJ, Bakris GL: Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension 46:637-642, 2005
55. Lindholm LH, Carlberg B, Samuelsson O: Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545-1553, 2005
56. Morgan TO, Anderson AIE, MacInnis RJ: ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertension 14:241-247, 2001
57. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, Raskin P, Wright JT Jr, Waterhouse B, Lucas MA, Anderson KM, Bell DSH, for the GEMINI Investigators: Differential effects of β-Blockers on albuminuria in patients with type 2 diabetes. Hypertension 46:1309-1315, 2005
58. Barzilay JI, Davis BR, Bettencourt J, Margolis KL, Goff DC Jr, Black H, Habib G, Ellsworth A, Force RW, Wiegmann T, Ciocon JO, Basile JN, ALLHAT Collaborative Research Group: Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens 6:116-125, 2004
59. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsuch W, Sowers J: Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 36:646-661, 2000
60. Savers JR, White WB, Pitt B, Whelton A, Simons LS, Winer N, Kivitz A, Van Ingen H, Brabant T, Fort JG: The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 165:161-168, 2005
61. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ, Stout R, Vallbona C, Winston MC, Karimbakas J, the National Blood Pressure Education Program Coordinating Committee: Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA 288:1882-1888, 2002